Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ufp Technologies (UFPT) Other Accumulated Expenses (2011 - 2024)

Ufp Technologies posted quarterly Other Accumulated Expenses of $7.7 million for Q4 2024, up 18.91% year-on-year from $6.5 million in Q1 2024, and up 18.91% on a QoQ basis from $6.5 million in Q4 2023.

Ufp Technologies (UFPT) has 14 years of Other Accumulated Expenses data on file, last reported at $7.7 million in Q4 2024.

  • For the quarter ending Q4 2024, Other Accumulated Expenses rose 18.91% year-over-year to $7.7 million; the trailing twelve-month figure through Dec 2024 stood at $7.7 million (up 18.91% YoY), and the FY2024 full-year result was $7.7 million, up 18.91% from the prior year.
  • Other Accumulated Expenses for Q4 2024 stood at $7.7 million, up from $6.5 million in the prior quarter.
  • Across five years, Other Accumulated Expenses topped out at $7.7 million in Q4 2024 and bottomed at $2.2 million in Q4 2020.
  • The 5-year median for Other Accumulated Expenses is $4.8 million (2022), against an average of $5.1 million.
  • The widest annual swing landed in 2020, when Other Accumulated Expenses rose 2.67%; it then surged 94.4% in 2021.
  • A 5-year view of Other Accumulated Expenses shows it stood at $2.2 million in 2020, then soared by 94.4% to $4.3 million in 2021, then increased by 10.44% to $4.8 million in 2022, then surged by 34.72% to $6.5 million in 2023, then rose by 18.91% to $7.7 million in 2024.
  • The last three Other Accumulated Expenses figures came in at $7.7 million (Q4 2024), $6.5 million (Q4 2023), and $4.8 million (Q4 2022), per Business Quant data.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Abbott Laboratories 152.82 Bn 146.17 Bn 6.27 Bn
2 Stryker 115.07 Bn 112.19 Bn 3.81 Bn
3 Medtronic 95.25 Bn 87.08 Bn 5.76 Bn
4 Boston Scientific 71.38 Bn 70.17 Bn 3.61 Bn
5 Edwards Lifesciences 51.08 Bn 47.41 Bn 1.29 Bn
6 Koninklijke Philips 29.38 Bn 26.07 Bn 2.07 Bn
7 Dexcom 28.84 Bn 27.72 Bn 750.30 Mn
8 GE HealthCare Technologies 28.56 Bn 26.49 Bn 1.98 Bn
9 Steris 20.71 Bn 20.30 Bn 697.10 Mn
10 Ufp Technologies 1.69 Bn 1.67 Bn 44.36 Mn

Historic Data

Download Data 🔒
DateValue
Dec 31, 2024 7.68 Mn
Dec 31, 2023 6.46 Mn
Dec 31, 2022 4.79 Mn
Dec 31, 2021 4.34 Mn
Dec 31, 2020 2.23 Mn
Dec 31, 2019 2.17 Mn
Dec 31, 2018 2.63 Mn
Dec 31, 2017 1.30 Mn
Dec 31, 2016 1.12 Mn
Dec 31, 2015 1.42 Mn
Dec 31, 2014 1.49 Mn
Dec 31, 2013 1.28 Mn
Dec 31, 2012 1.96 Mn
Dec 31, 2011 1.14 Mn